Pets hold a special place in our hearts, often regarded as cherished members of our families. Pets bring joy, companionship, and unreserved love into our lives in the form of the wagging tails of loyal dogs, contented cats, playful rabbits, and comforting purrs of cats. Statistics on pet ownership show that 66% of households in the United States, or 86.9 million homes, will have a pet by 2024. This is a significant increase from the reported 56 percent in 1988. Among pets, dogs rank as the most favoured companion, with 65.1 million households owning a dog, followed by cats (46.5 million households) and freshwater fish (11.1 million households). As pet ownership continues to rise worldwide, so does the responsibility to provide them with the best possible care.
Just like humans, pets require medical attention to maintain their health and well-being. From routine check-ups and vaccinations to treatment for illnesses and injuries, veterinary care is essential for ensuring that our furry friends lead happy and healthy lives. However, the availability of effective medications and treatments has a significant impact on the quality of this care. This is where pet medicine companies come into play. These companies are at the forefront of research, development, and manufacturing of pharmaceuticals, vaccines, and other healthcare products specifically designed for animals. Veterinarians are able to diagnose, treat, and prevent a wide range of illnesses and conditions in pets thanks to their dedication to advancing the field, ultimately enhancing their quality of life.
According to TechSci Research report “Companion Animal Pharmaceuticals Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029 Segmented By Indication (infectious diseases, dermatologic diseases, pain, orthopedic diseases, behavioral diseases, other), By Animal (dogs, cats, horses, other), By Distribution Channel (veterinary hospitals and clinics, retail pharmacies, Others), By Region and Competition,” the Global Companion Animal Pharmaceuticals Market was valued at USD 14.52 Billion in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 8.25% through 2029.
The market growth is driven by increasing pet ownership. An essential catalyst for the expansion of the companion animal pharmaceuticals market is the increasing global population of pet owners. For instance, India holds the position of the sixth largest nation in terms of total dog ownership thanks to its estimated 10,200,000 canine residents. With approximately 69,929,000 dogs, the United States leads, followed by China with 27,400,000 and Russia with 12,520,000. With 12,500,000 dogs, Japan comes in fourth, followed by the Philippines with 11,600,000.
The demand for veterinary medications and healthcare products has increased as more people welcome pets into their homes and families. This trend is particularly prominent in urban areas and among younger demographics, where pet ownership is on the rise. Additionally, there has been a discernible shift in the attitudes of pet owners toward their animals, as many now regard them as essential members of the family. Pet owners’ willingness to invest in their pets’ well-being has increased as a result of this trend toward humanizing animals. In 2022, Americans demonstrated their commitment to their pets by spending USD 136.8 billion, marking a substantial 11% rise from the 2021 expenditure of USD 123.6 billion. As a result, there is an escalating demand for top-tier pharmaceuticals and healthcare products tailored to meet the specific requirements of companion animals, encompassing preventive care, nutritional supplements, and treatment options for diverse medical conditions. Besides, comparable to demographic trends in human populations, the pet demographic is also undergoing aging, resulting in a rise in the incidence of age-related ailments and chronic illnesses among companion animals.
Pharmaceuticals and healthcare solutions specifically designed to meet the requirements of elderly pets are in high demand as pets live longer lives. This encompasses medications targeting conditions such as arthritis, cognitive impairment, and other age-related maladies, consequently stimulating growth within the companion animal pharmaceuticals sector.
Top Pet Medicine Companies
Zoetis USA
Zoetis Inc. stands as a global frontrunner in the animal health sector, with a steadfast focus on the exploration, development, manufacturing, and commercialization of an extensive range of products and services.
This comprehensive portfolio encompasses medicines, vaccines, diagnostic products, biodevices, genetic tests, and precision animal health technology. The company sells its products to eight primary species, including dogs, cats, horses, cattle, swine, poultry, fish, and sheep, in addition to a wide range of other animals. In addition, Zoetis sells parasiticides, vaccines, anti-infectives, dermatology, other pharmaceutical products, medicated feed additives, and animal health diagnostics. The companion animal product line not only serves to enhance and prolong the quality of life for pets but also enhances convenience and compliance for pet owners. Moreover, these products aid veterinarians in enhancing the quality of care and optimizing the efficiency of their practices. About 64% of the company’s revenue came from companion animal products during the fiscal year that ended December 31, 2022.
In 2022, Zoetis executed the acquisition of Jurox, an esteemed animal health enterprise based in Australia. This strategic move bolsters Zoetis’ portfolio with a range of companion animal and livestock products, while also opening avenues for future growth, expanding manufacturing capabilities, and enhancing market presence in Australia. In addition, Zoetis acquired Basepaws in the same year, a leading pet care genetics company that specialized in genetic tests, analytics, and early health risk assessments for pets. This acquisition gives pet owners and veterinarians valuable insights into a pet’s disease risk, making it easier to take an active role in early disease detection and treatment.
Animal Health USA Inc. Of Boehringer Ingelheim
Boehringer Ingelheim Animal Health is a prominent global leader in the animal health industry, dedicated to enhancing the health and well-being of animals worldwide. Boehringer Ingelheim Animal Health is a well-known pharmaceutical company’s subsidiary that operates with an unwavering dedication to veterinary medicine innovation, research, and excellence. Boehringer Ingelheim is a leading provider of vaccines and therapeutics in its Animal Health division, with a wide range of products for a wide range of animals. This includes items made specifically for horses, pets, and livestock like swine, ruminants, and poultry.
Key brands within its portfolio, including NEXGARD®, FRONTLINE, and HEARTGARD®, serve as cornerstones of the company’s success in the companion animal segment. In addition, Boehringer Ingelheim’s Animal Health division has long-term partnerships. For instance, the company collaborated with MabGenesis Inc., a biopharmaceutical enterprise, to expedite the discovery and development of novel monoclonal antibodies intended for potential canine therapies. Furthermore, Boehringer Ingelheim has initiated a research cooperation with CarthroniX, focusing on the development of small-molecule therapies in canine oncology. Boehringer Ingelheim’s commitment to improving animal health is exemplified once more by this strategic alliance, which aims to discover novel molecules for the treatment of canine cancer.
Elanco Animal Health Services, Inc.
Elanco Animal Health Incorporated and its subsidiaries are a global leader in the animal health industry that is dedicated to innovation and the provision of products and services that aim to treat and prevent diseases in farm animals as well as pets. The company works with farmers, pet owners, veterinarians, and the general public to try to create value and help its customers improve the health of the animals they care for. With a diverse and robust product portfolio, distributed in over 90 countries, Elanco serves a multitude of animal species, primarily focusing on dogs, cats, cattle, poultry, swine, sheep, and aquaculture.
The Advantage Family (for cats and dogs), Seresto (for cats and dogs), Rumensin (for cattle), Credelio Family (for cats and dogs), and Maxiban (for poultry) were Elanco’s most popular products and product families in 2023. In 2023, these products and product families made up about 31% of the company’s total revenue. Elanco’s pet health products are made to help pets live longer, get healthier, and be more active around the world. Vaccines, therapeutics, and parasiticides make up the majority of the global pet health portfolio of the company. Elanco’s wide range of indications, species coverage, and formulations make it one of the most extensive parasiticide portfolios in the pet health market. Its products are made to protect pets from fleas, ticks, and internal parasites so that they can continue to live and play.
Ceva Santé Animale
Ceva Santé Animale, led by seasoned veterinarians, ranks as the 5th largest global animal health enterprise. Dedicated to providing cutting-edge health solutions for all animals, the company prioritizes delivering the highest standard of care and well-being. Notably, Ceva Santé Animale holds the distinction of being the foremost French entity in the animal health sector, with its headquarters situated in Libourne, France.
With a history spanning over 20 years, Ceva Santé Animale has firmly established itself as a trusted partner to veterinarians, farmers, pet owners, and animal health professionals across the globe. The company’s diverse portfolio encompasses pharmaceuticals, vaccines, biologics, and healthcare products tailored to meet the unique needs of animals in various sectors.
Through the acquisition of three businesses in the third quarter of 2022, Ceva Santé Animale witnessed the incorporation of over 200 new team members into the One Ceva community and Biotecnofe, a pioneering biotech startup that makes innovative products for Zoovet to sell.
